Month: April 2026

Meet with Christopher Kata and Nick Travers at the SCDM EMEA meeting in Denmark!

04/14/2026

Meet with Christopher Kata, Director of Sales & Marketing and Nick Travers May 3rd – 6th at the SCDM EMEA meeting being held in Copenhagen, Denmark! If you’re attending be sure to to reach out to Christopher and Chris to schedule a one on meeting or just drop by booth at your convenience! We’re looking…

Phanes Therapeutics announces dose expansion in clinical study of spevatamig in combination with chemotherapy for treatment of biliary tract cancer

04/14/2026

Excerpt from the Press Release: SAN DIEGO, April 7, 2026 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today the initiation of the dose expansion phase in their clinical study evaluating spevatamig in combination with chemotherapy for the treatment of biliary tract cancer…

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

04/10/2026

Excerpt from the Press Release: LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with…

New Vulnerability in Aggressive Leukemia Discovered by Researchers

04/09/2026

Excerpt from the Press Release: A potential weakness in a common form of leukemia could lead to new treatments. The discovery, made by researchers at the Lewis Katz School of Medicine at Temple University, shows that leukemia cells with mutations in DNMT3A—a gene often altered in acute myeloid leukemia (AML)—depend on a DNA-repair enzyme known as DNA polymerase…

Abcuro Presents Results from Phase 2/3 MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis at GCOM 2026

04/08/2026

Excerpt from the Press Release: NEWTON, Mass.–(BUSINESS WIRE)–Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026 in Lisbon, Portugal from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients…

Imperative Care Initiates CLEAR-IT Clinical Study to Address Critical Gaps in Clinical Standards for Peripheral Thromboembolism

04/07/2026

Company Announces First Patient Enrolled in CLEAR-IT Study Evaluating Symphony and Prodigy Thrombectomy Systems for Vascular Disease Excerpt from the Press Release: CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the enrollment of the first patient in the CLEAR-IT Study, a prospective,…

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

04/06/2026

Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET fusion-positive NSCLC Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 31, 2026 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication…

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

04/01/2026

TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath® as a Stand-Alone Device for Drug-Delivery in Oncology Management Excerpt from the Press Release: MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or “the Company”)…